Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 vs Lucentis in diabetic macular edema (DME)
CTR20243362Phase 3Active
- Sponsor
- BeiGene
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT5906 in diabetic macular edema (DME), sponsored by BeiGene. Started Nov 2024; status: active.
02
Drugs
BAT5906
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20243362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243362.